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Abstract
Skeletal-related events occur in 80% of patients with multiple myeloma (MM). Osteoporosis, 
osteoclastic destructions, pathological fractures of the bone, spinal cord and compression 
can impair patients’ quality of life and reduce survival. Many imaging techniques can be 
used for the detection of MM bone lesions. Many clinical studies suggest modern imag-
ing techniques for their greater sensitivity. Radiotherapy is a treatment of choice for soli-
tary plasmacytoma of the bone and extramedullary plasmacytomas. However, radiation 
treatment of MM can be used as a palliative approach for uncontrolled pain, impending 
pathological fractures and in the cases of spinal cord compression. Radiotherapy induces 
analgesic effect in 75–100% of patients and promotes a recalcification in 40–60%. In patients 
with spinal cord compression, radiation therapy is given along with dexamethasone, and 
up to half of patients may experience improvement. It is well known that pain perception, 
response to analgesics and pain relief effect of radiotherapy are quite different for multiple 
myeloma patients. Clinical, laboratory and genetic factors may influence the pain percep-
tion and analgesic effect of radiotherapy. Side effects of radiation are generally mild, are 
limited to the radiotherapy site and can be predicted.
Keywords: multiple myeloma, bone disease, analgesic effect, palliative radiotherapy, 
radiation dose
1. Introduction
Skeletal-related events are one of the signs of multiple myeloma (MM) [1, 2]. Osteoclastic 
destructions increase the risk of pathologic fractures and spinal cord compression syn-
drome, which reduces patients’ quality of life, increases treatment costs and worsens patient 
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survival [3]. Radiotherapy is a treatment approach used in patients with solitary plasmacy-
tomas. However, the role of radiation treatment of MM is palliative: to induce an analgesic 
effect in osteolytic lesions, to promote recalcification in the sites of impending pathological 
fractures and symptom control in spinal cord compression [4].
Despite the enormous development in MM treatment approaches and response to sys-
temic therapy, patients are often in need of pain control due to slow repair of bone lesions. 
Chemotherapy treatment alone is insufficient for patients suffering from pain caused 
by osteolytic bone destruction or in case of an impending fracture at the destruction site. 
Seventy percent of patients receive radiation at least once during their MM therapy [5]. Where 
radiotherapy is applied, pain can be reduced by 75–100% from the starting level [5–12]. 
Recalcification of bone destructions caused by MM is observed in 40–60% of the cases after 
radiation treatment [5, 7, 12, 13]. Good results in the treatment of bone damages due to MM 
can be achieved when applying other supportive therapy measures, such as bisphosphonates, 
vertebroplasty and surgery methods, alongside radiation therapy.
It has been known for a long time that pain perception is not the same for all patients. The 
response to analgesics, pain relief and the effect of radiotherapy are very individual. The above 
can be determined by a different secretion of anti-inflammatory cytokines (IL-6, IL-10, TNFα, 
IL-1), which participate in the pathogenesis of the pain caused by a chronic disease and their 
concentration in blood serum. Circulating cytokines and inflammatory proteins are related to 
pain, cognitive functions, depression, fatigue and sleep disturbances [14–16]. The secretion of 
anti-inflammatory cytokines is regulated genetically. Cytokine genes are very polymorphous. 
Polymorphisms in regulatory regions, including promoters and non-transmittable areas, in a 
majority of the cases can change the gene expression in vitro [15]. Thus, the above has an impact 
on the secretion of cytokines and their concentration in blood serum, which determines the 
pain perception threshold and a different response of patients to analgesics and radiotherapy.
2. The role of imaging
Around 70–80% of patients have osteolytic lesions at diagnosis of MM, and up to 90% develop 
lytic lesions during the course of the disease [17]. The International Myeloma Working Group 
updated criteria for the diagnosis of symptomatic MM and revealed the value of modern imag-
ing such as computed tomography (CT), whole-body low-dose computed tomography (LDCT), 
positron emission tomography/computed tomography (PET/CT) and magnetic resonance imag-
ing (MRI) [18]. Modern imaging techniques had a greater sensitivity than conventional radio-
graphic skeletal survey for the detection of MM bone lesions with as many as 80% or more 
lesions detected by the newer imaging techniques [18]. A summary of different imaging tech-
niques is detailed in Table 1.
2.1. Conventional radiographic skeletal survey
Whole-body X-rays imagine (including plain radiographs of the whole skeleton) have been 
widely used for the detection of bone lesions at diagnosis and during the course of the disease. 
Osteolytic bone lesions are more common in the scull, vertebrae, ribs and pelvis. Although the 
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Imaging technique Advantages Limitations
Whole-body skeletal survey Low cost Low sensitivity
Available in many centres Only advance bone disease could 
be detected
Validated technique Reduced for the differential 
diagnosis between malignant and 
benign fractures
Difficulty to assess certain areas
Lack of detection of lytic lesions 
response to the treatment
Dependent on the observer
Imaging process is long and not 
well tolerable for patients
Whole-body low-dose computed 
tomography
A higher diagnostic sensitivity for the 
detection of osteolytic bone lesions
More expensive then whole-body 
skeletal survey
Higher-quality images for planning 
biopsies and therapeutic interventions
Approach is available in some 
centres
A low radiation dose compared with 
standard CT
Reduced for the differential 
diagnosis between malignant and 
benign fractures
Superiority in estimating fracture risk 
and bone instability
Unclear prognostic significance
Shorter duration of the examination
Magnetic resonance imaging A high sensitivity for the early 
detection of marrow infiltration by 
myeloma cells
High cost
More sensitive in detecting 
multiple bone lesions and exclude 
asymptomatic myeloma
Imaging process is long and not 
well tolerable for patients
The ability to detect spinal cord or 
nerve compression and the presence 
of soft-tissue masses
Unsuitable for patients with metal 
objects, contrast contraindicated
Higher-quality images for planning 
biopsies and therapeutic interventions
Valuable for differential diagnosis 
between malignant and benign 
fractures
Prognostic significance
No radiation exposure
Positron emission tomography/
computed tomography
A higher accuracy approach for the 
early detection of lesions and exclude 
asymptomatic myeloma
High cost
Useful to evaluate disease activity 
before and after treatment
Lack of availability in many centres
Detects osseous and extramedullary 
disease
Limited by false-positive results of 
inflammation
A better definition of complete 
response and minimal residual 
disease
Lack of standardisation
Prognostic significance
Table 1. A summary of different imaging techniques for multiple myeloma patients.
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whole-body X-ray was the standard of care for many years, it has several limitations: for a lytic 
lesion to become apparent, more than 30% loss of trabecular bone must occur; it is difficult to 
assess certain areas, such as the pelvis and the spine; there are limitations: the detection of lytic 
lesion response to anti-myeloma therapy because of a delayed evidence of healing; specificity 
is reduced for the differential diagnosis of myeloma-related fracture and benign fracture (very 
important, particularly in cases of new vertebral compression fractures in the absence of other 
criteria of relapse); it is dependent on the observer, and studies are long and often not tolerable 
for patients in severe pain [19].
2.2. Whole-body low-dose computed tomography
Whole-body LDCT allows the detection of osteolytic bone lesions in the whole skeleton with 
a greater sensitivity and a low radiation dose compared with standard CT. Advantages of 
whole-body LDCT over conventional skeletal survey include a higher diagnostic sensitivity 
for the detection of osteolytic lesions, especially in areas where the whole-body X-ray detec-
tion rate is low (i.e. pelvis and spine); superiority in estimating fracture risk and bone instabil-
ity; shorter duration of the examination, which is an important issue for patients in pain; the 
production of higher-quality images for planning biopsies and therapeutic interventions; and 
the demonstration of unsuspected manifestations of myeloma or other diseases [19]. Major 
deficiencies of whole-body LDCT are the lack of specificity for the differential diagnosis 
between malignant and osteoporotic fractures and also the fact that this diagnostic approach 
is available in some centres only. In several studies, whole-body LDCT was found to be supe-
rior to whole-body X-ray for the detection of osteolytic lesions [19]. In one retrospective study, 
the total number of bone lesions detected by whole-body LDCT was 968 and the number of 
bone lesions detected by whole-body X-ray was only 248 (p < .001), which means that 61% of 
patients with normal whole-body skeleton X-ray images had more than one osteolytic bone 
lesion on the whole-body LDCT scan, and such patients should receive antimyeloma therapy 
[20]. This was confirmed by another prospective study, where whole-body LDCT revealed 
osteolytic bone lesions in 23% of patients with negative conventional radiographic skeletal 
X-ray scans, especially in the axial skeleton (p < .001) [21]. The same study proved that whole-
body LDCT is superior in detecting lesions in patients with osteopaenia and osteoporosis [21].
2.3. Magnetic resonance imaging
MRI has been established as a valuable technique for imaging multiple myeloma because of 
its superior soft-tissue contrast resolution. MRI has a high sensitivity for the early detection of 
marrow infiltration by myeloma cells. Five MRI patterns of marrow involvement have been 
recognised in multiple myeloma: a focal pattern that consists of localised areas of myeloma 
cell infiltration of 5 mm or greater in diameter, a diffuse pattern characterised by an almost 
complete replacement of normal marrow by myeloma cells, a combined diffuse and focal 
pattern, a normal bone marrow pattern and a variegated or “salt and pepper” pattern with 
innumerable small bone marrow focal lesions [19].
Several studies showed that MRI is generally more sensitive in detecting multiple lesions 
compared to conventional radiographic skeletal survey. The systematic review of studies 
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compared modern and conventional imaging techniques in the detection of bone lesions 
and confirmed the superiority of MRI over conventional skeletal X-ray, mainly in the axial 
skeleton [22].
Because of its high sensitivity in revealing bone marrow involvement, MRI is now used for 
the discrimination between smouldering and symptomatic multiple myeloma. Several stud-
ies have shown that approximately 40–50% of patients with normal whole-body X-ray scan 
had abnormal findings on MRI examinations [19].
MRI has the ability to detect spinal cord or nerve compression and the presence of soft-tissue 
masses and is recommended in patients with extraosseous lesions. MRI is the approach to 
define the degree of involvement and to evaluate for cord compression for surgical interven-
tion or radiation therapy. Unfortunately, almost any skeletal tumour has the same signal-
intensity profile as multiple myeloma. MRI is not disease-specific, and additional tests should 
be used to establish the diagnosis of multiple myeloma. MRI is also recommended for patients 
with a solitary bone plasmacytoma. MRI may demonstrate unsuspected bone lesions, and for 
such patients, systemic treatment must be given instead of radiation therapy, which is the 
treatment of choice for solitary bone plasmacytoma.
MRI also can provide important information for prognosis. Patients with diffuse MRI pattern 
experienced a poorer overall survival (OS) compared with patients with focal or normal pat-
terns [19]. One study of 611 multiple myeloma patients showed that the presence of more than 
seven focal lesions was an independent predictor of poorer prognosis and that resolution of 
all focal lesions was an indicator of superior survival [23].
The major advantage of MRI over the whole-body LDCT or conventional CT is the discrimi-
nation between myelomatous and normal marrow. This is extremely helpful to differentiate 
myeloma from osteoporotic fractures in more than 90% of cases [19].
2.4. Positron emission tomography/computed tomography
PET/CT is a new imaging technique, which can be applied in the diagnosis, stage and progno-
sis of tumour and to evaluate the efficacy of the treatment. PET/CT provides information about 
the sites and number of lesions, hypermetabolic activity of the involved area (depending on 
F-18 fluorodeoxyglucose (FDG) uptake). Furthermore, PET/CT detects osseous and extramed-
ullary disease in patients at diagnosis and relapse. PET/CT is a higher accuracy approach than 
traditional imaging techniques in the diagnosis of multiple myeloma. However, there is no 
uniform conclusion about the diagnostic accuracy of PET/CT for multiple myeloma because 
of the controversy on the variety of results.
The large meta-analysis has shown that PET/CT is more sensitive compared with conven-
tional skeletal X-ray for the detection of bone lesions in multiple myeloma [22]. The higher 
detection rate of PET/CT over conventional skeletal X-ray scan for the presence of osteolytic 
lesions is especially important for patients with smouldering multiple myeloma. In the stud-
ies related to smouldering multiple myeloma, 16–39% of patients with normal whole-body 
X-ray had positive PET/CT results [19]. The probability of progression to symptomatic mul-
tiple myeloma within 2 years was 58–75% for patients with a positive PET/CT [19].
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PET/CT may be used for the diagnosis of solitary bone plasmacytoma and extramedullary 
disease. It is not clear whether PET/CT or MRI is more preferable. PET/CT also has a value for 
patients with nonsecretory or oligosecretory MM for the detection of active lesions.
PET/CT has been tested for a better definition of complete response (CR) to MM therapy and as 
an independent factor for survival prognosis at diagnosis and after treatment. Approximately 
30% of patients at CR had a positive PET/CT. In addition, PET/CT negativity was an indepen-
dent predicted factor for prolonged PFS and OS in patients with a CR, patients with a positive 
PET/CT in CR and median PFS was 50 months compared to 90 months for patients with a 
negative PET/CT [24].
However, PET/CT remains a high-cost method, and there is lack of availability in many cen-
tres and may be limited by false-positive results caused by inflammation from other underly-
ing diseases.
3. Radiotherapy for solitary plasmacytomas
The solitary plasmacytoma is a localised accumulation of monoclonal plasma cells without 
systemic plasma cell disease manifestation. Regarding location, it can be classified into soli-
tary plasmacytoma of bone (SBP) and extramedullary plasmacytoma (EMP) [25]. SBP gener-
ally occurs in the vertebra and skull; however, EMP is most frequently observed in head and 
neck [25]. Plasmacytomas are radiosensitive neoplasms, and radiotherapy has a potentially 
curative effect for both SBP and EMP [4].
3.1. Radiotherapy for solitary plasmacytoma of bone
Radiotherapy with a curative intent is the treatment of choice, resulting in local control in more 
than 80% of patients with SBP [25, 26]. In some cases, as bone instability, rapid progression of 
neurological symptoms and surgical intervention are required, the results of surgery alone are 
not optimal and carry high rates of local relapse [27]. Currently, the standard of treatment for 
SBP is radiotherapy. Optimal-dosing guidelines have not been established due to the absence 
of prospective randomised studies. The United Kingdom Myeloma Forum recommend radio-
therapy at least 40 Gy in 20 fractions [28]. For bulky disease (>5 cm), a higher-dose 50 Gy in 25 
fractions was recommended [28]. Approximately 30% of patients who received higher doses 
than 50 Gy remained without evidence of any local disease failures [25]. In clinical practice, a 
radiation dose of 45–50 Gy in 20–25 fractions is recommended for the treatment of SBP.
The optimal target volume for radiotherapy planning in SBP is to encompass the tumour vol-
ume plus a margin of at least 1.5–2 cm on the tumour detectable by MRI [25, 26]. In case of ver-
tebral involvement, fields typically include one to two uninvolved vertebrae above and below 
the affected level [25]. Prophylactic regional lymph node irradiation is not necessary in SBP.
3.2. Radiotherapy for extramedullary plasmacytoma
Like SBP, EMPs are highly radiosensitive; almost all patients (80–100%) achieve local control, 
and approximately 50–65% of patients remain free of disease longer than 10 years [26]. Due 
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to a lesser number of patients and the absence of randomised prospective studies, the opti-
mal dose of radiotherapy is not established. Current evidence-based recommendations by 
the United Kingdom Myeloma forum are similar to those for SBP [28]. The recommendations 
include radiotherapy dose of 40 Gy in 20 fractions for tumours of <5 cm and up to 50 Gy in 25 
fractions for tumours of ≥5 cm with at least a 2-cm margin encompassing the primary tumour 
[28]. If cervical nodes are involved (or in Waldeyer’s ring tumours), these should be included 
in the radiotherapy field [28].
Surgery may be an acceptable treatment method combined with radiotherapy. A combination 
of a higher dose of radiation and surgery predicted for better PFS [25]. Surgical procedures 
of the head and neck are not recommended, but surgery may be considered for other sites of 
the disease [26].
4. Indications for radiotherapy in multiple myeloma
Radiotherapy can produce a curative effect for both solitary plasmacytoma of bone and extra-
medullary plasmacytomas; however, its role in the treatment of MM patients is only pallia-
tive. The most common indications for radiotherapy in MM are pain relief in the sites of bone 
destructions, the prevention of pathological fractures or to decrease the pain in the fracture 
site, to evoke the recalcification, the management of spinal cord compression syndrome and 
the treatment of extramedullary disease.
4.1. Palliation for pain
Pain is the most common symptom experienced by MM patients. Up to 67% of patients report 
pain at diagnosis, and it may be present for several months before the diagnosis [29]. Local 
radiotherapy is effective for pain relief. It produces an analgesic effect by inhibiting chemical 
pain mediators and causing tumour shrinkage. There is a debate on the effect of radiation 
dose on pain relief.
Results of randomised clinical studies revealed the same effect of pain relief when applying 
two different radiotherapy regimens (8 Gy/1 fr and 3 Gy × 10 fr) for the treatment of patients 
with solid tumour metastases, though the application of a single fraction of 8 Gy treatment 
produces more recurrent treatment episodes [30–33]. The earlier data, however, cannot be 
directly applied in the treatment of patients with MM, since their future prospects are bet-
ter (the average survival reaches 30–40 months), whereas the average survival among the 
patients with solid tumour metastases in bones is about 9 months [5]. In the meta-analyses by 
Sze et al. [34] and Wu et al. [35], no significant difference in the overall and complete response 
in pain reduction between single- (SF) and multiple-fraction (MF) palliative radiotherapy was 
observed. Chow et al. in the systematic review analysed 16 randomised trials comparing SF 
versus MF for bone metastases: no significant difference was found regarding response rates 
[30]. An increased risk for pathological fractures and spinal cord compressions was observed 
in the SF regimen, which was statistically insignificant, while retreatment in the SF regimen 
was 2.5-fold higher [30]. The role of different palliative radiotherapy regimens for MM is not 
well established due to lack of clinical trials. Medical literature provides only a small number 
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of studies dealing with various radiotherapy regimens for the treatment of patients with mul-
tiple myeloma as well as impact of the radiotherapy regimen on pain relief at the sites of bone 
destructions [5–12]. However, final recommendations concerning the choice of the radiation 
therapy regime have not been presented yet.
Some clinical studies did not find a significant difference between the radiation dose and 
pain relief after radiotherapy [5, 8, 10, 12]; however, Adamietz et al. [6] and Minova et al. 
[11] reported that for adequate pain relief, higher doses would be obtained. Pain relief 
occurred in 80–92% [6, 11]. Adamietz et al. affirmed that local long-term palliation effect can 
only be achieved by a high radiation dose [6], whereas Leigh et al. analysed 101 patients and 
observed pain reduction in 97% of patients (complete in 26%) with a median dose 3–60 Gy. 
Only 6% of patients were retreated for the relapse which occurred after a median interval 
of 16 months [10]. This study showed the durable symptom relief after a mean total dose of 
10 Gy [10].
Clinical, laboratory and genetic factors may influence pain perception and analgesic effects 
of radiotherapy. Retrospective studies published by Adamietz et al. [6] and Mose et al. [12] 
indicated that the incidence of pain relief was higher in patients treated with concurrent 
chemotherapy which had a significant impact on a positive response to radiotherapy, but 
other studies did not show this relationship [5, 10]. Mose et al. reported that not only concur-
rent chemotherapy but also the Karnofsky performance above 70% had a significant impact 
on a positive analgesic response to radiation treatment, whereas the total radiation dose, 
gender, age, irradiated site and bisphosphonates had no effect on pain relief [12]. In other 
study performed by Stolting et al., significant parameters for pain relief in the multivariate 
analysis were completeness of therapy, patients younger than 60 years and a single dose of 
2 Gy; other parameters like Karnofsky index, concurrent chemotherapy and total dose were 
insignificant [5].
Medical literature provides several studies which have revealed that the polymorphism of 
inflammatory cytokine genes influences pain perception and analgesics dose. Furthermore, 
the altered levels of fatigue, depression and response to analgesics in pancreatic, lung or 
breast cancer have been described [15, 36–43]. These types of studies, however, have not been 
conducted for patients with multiple myeloma, though during the formation of bone destruc-
tions, anti-inflammatory cytokines are emitted by plasma cells and bone marrow stroma cells. 
No study has been performed worldwide, which would deal with the impact of polymor-
phism of genes encoding for cytokines in response to radiotherapy.
Hundred and one patients were involved in a randomised prospective clinical study per-
formed at the Lithuanian University of Health Sciences [44]. Two different radiation treatment 
regimens of bone destructions due to multiple myeloma were compared. MF radiotherapy 
regime (3 Gy × 10 fr) was applied to 58 patients and SF (8 Gy × 1 fr) regime was applied to 
43 patients. Pain relief was obtained in 84.5% of patients in MF regimen group (complete 
response 69.4%) and 74.4% of patients in SF regimen group (complete response 68.8%). No 
significant differences were observed in analgesic response between the groups. No signifi-
cant differences were observed in the period of time before reaching the analgesic effect of 
radiotherapy: in both groups, analgesic effect was achieved in the first 4 weeks.
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Univariate statistical analysis revealed that the age under 65 years (p = 0.016), stage II of the 
disease (according to Durie-Salmon classification) (p = 0.03) and recalcification in the irradi-
ated site (p = 0.011) were significant parameters for analgesic response after radiotherapy, 
whereas other parameters (gender, Karnofsky index, paraprotein type, haemoglobin level, 
surgery, pain score at the admission, total radiation dose, bisphosphonates and concurrent 
chemotherapy) were not significant.
All parameters mentioned earlier were included in binary logistic regression model for the 
analysis of their influence to pain relief. Using a stepwise variable removal method (backward 
conditional), it was found that the following attributes have a significant impact on analgesic 
response after radiation treatment for pain relief: female gender, age under 65, IgG MM type 
and the presence of recalcification in the irradiated site. Other factors analysed, including 
the total radiation dose, were not significant for pain relief after radiation treatment. Results 
of analgesic response from clinical trials of palliative radiotherapy in the treatment of MM 
patients are shown in Table 2.
The study performed by Rudzianskiene et al. involved analysis of 12 gene polymorphisms of 
six cytokines (IL-6, IL-10, TNFα, IL-1α, IL-1β and IL-1RA) participating in the pathogenesis of 
the pain syndrome in bone destruction sites. The aim was to evaluate the influence of interleu-
kins on the perception of pain and response to radiotherapy in MM patients [44].
Univariate statistical analysis was used to assess associations between severe pain status (8–10 
points on VAS) before radiation treatment and genotype groups of each cytokine gene stud-
ied. None of the genotypes analysed was found to be significant for the perception of severe 
pain before treatment; yet, a marginal relation was observed that patients with GG genotype 
of IL1RN c.1812G > A polymorphism more often indicated severe pain before radiotherapy, 
compared to patients with GA and AA genotypes (relative risk (RR) 0.43; 95% confidence 
interval (CI) 0.18–1.06; p = 0.068) [44].
Multivariate logistic analysis included all the earlier clinical, demographic and symptom fac-
tors, as well as genotype groups of each cytokine gene analysed. Based on multivariate logistic 
regression, the following factors were determined to have a significant impact on severe pain 
before radiation treatment: Karnofsky index ≥60% and IL1RN c.1812G > A polymorphism GG 
genotype. Other factors analysed were not significant for the perception of severe pain before 
radiation treatment [44].
A comparison of a decrease in pain perception points before radiotherapy and during the 
monitored period, that is, after 4, 12 and 24 weeks, among patients with different genotypes 
was carried out. The analysis revealed that patients with IL-1α-encoding gene IL1A c.889C > T 
CC genotype had a significantly better response to radiation therapy and indicated milder 
pain after 12 and 24 weeks, compared to patients with TT and CT genotypes. Furthermore, 
patients with IL-1β-encoding gene IL1B c. 3953C > T CC genotype indicated significantly 
more often milder pain scores after radiotherapy in 12 and 24 weeks, compared to patients 
with TT and CT genotypes. Patients with IL-1RA-encoding gene IL1RN c.11100 T > C CC gen-
otype had a faster response to radiation therapy, that is, a significant decrease in pain points 
was observed after 4 weeks, compared to patients with TT and CT genotypes [44].
The Role of Radiology and Radiotherapy for Multiple Myeloma
http://dx.doi.org/10.5772/intechopen.75397
167
4.2. To evoke the recalcification
Multiple myeloma is a disease inducing osteolytic process which leads to an increased risk 
of pathologic fracture or spinal cord compression and severe pain with a negative impact on 
Clinical study Number 
of 
patients
Number of 
irradiated 
sites
Total 
dose 
(Gy)
Overall 
response 
(%)
Complete 
response 
(%)
Comments
Adamietz et al. [6] 70 70 2–30 39.6–80* n/a Local long-term palliation 
effect can only be achieved 
by high radiation dose and 
concurrent chemotherapy.
Leigh et al. [10] 101 306 3–60 91 n/a There was no significance 
difference between analgesic 
response and higher radiation 
dose, and there was no 
influence of concurrent 
chemotherapy.
Mose et al. [12] 42 71 18–45 85 34.3 There was no significance 
difference between analgesic 
response and higher radiation 
dose, response is better with 
concurrent chemotherapy.
Yaneva et al. [9] 87 87 17–20 89.6 26.9 The total dose relationship 
with an analgesic response 
has not been evaluated. 
Radiotherapy has no influence 
on overall survival.
Stolting et al. [5] 138 272 2–60 85.3 22.2 There was no significance 
difference between analgesic 
response and higher radiation 
dose, and there was no 
influence of concurrent 
chemotherapy.
Minowa et al. [11] 29 53 4–60 92 n/a Longer analgesic response was 
after higher radiation dose 
treatment.
Balducci et al. [7] 52 52 16–50 91 51.2 The total dose and concurrent 
chemotherapy relationship 
with an analgesic response has 
not been evaluated.
Rudzianskiene et al. 
[44]
101 101 8 Gy vs. 
30 Gy
74.4 vs. 
84.5
68.8 vs. 69.4 There was no significant 
difference between analgesic 
response and higher radiation 
dose, and there was no 
influence of concurrent 
chemotherapy.
*Without concurrent chemotherapy.
Table 2. A summary of published data on palliative radiotherapy analgesic response in the treatment of patients with 
MM.
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the quality of life. According to the study, recalcification is achieved after some months and 
occurs in 40–50% of the irradiated bone destructions in patients with multiple myeloma [5, 7, 
12, 13]. Palliative radiotherapy can be applied to avoid the impending or actual pathological 
fracture. However, the high-risk lesions should be first stabilised by orthopaedic measures 
and combined with post-operative radiation treatment for the improvement of pain and local 
control. Several retrospective studies, a majority of which included small patients’ cohorts, 
have demonstrated that there is no relation between the total radiation dose and recalcifica-
tion in the sites of bone destructions.
Mose et al. found that the stabilisation of the irradiated bone could be achieved in 46.4% of 
cases, and concurrent chemotherapy reinforces this effect [12]. Also, Stolting et al. reported a 
recalcification rate of 44.7% and the importance of concurrent chemotherapy for recalcifica-
tion [5]. The study performed by Rudzianskiene et al. showed an overall response of recalci-
fication with single-fraction radiotherapy of 35.9%, and in multi-fraction radiotherapy group, 
the response rate was 32.1% [44]. Binary logistic regression did not show a significant impact 
of concurrent chemotherapy on recalcification [44].
Koswig and Budach [45] found that an MF regimen (3 Gy × 10) significantly increases the bone 
density in the area of metastases from solid tumours compared with single fraction (8 Gy) in 
contrast to pain relief effect; also, Stolting et al. reported that recalcification was detected at 
total doses of >40 Gy for MM patients [5]. Balducci et al. found recalcification in 50% cases with 
a median total dose of 38 Gy and reported the importance of the early using of radiotherapy 
to avoid pathological fractures [7]. However, the studies published by Mose et al. [12] and 
Rudzianskiene et al. [44] did not show any influence of the total radiation dose on recalcification.
Mose et al. reported that not only concurrent chemotherapy but also the Karnofsky index 
above 70% and bisphosphonates had a significant impact on a positive recalcification effect 
to radiation treatment [12]. Also, in a clinical study performed by Rudzianskiene et al., the 
Karnofsky index more than 60% has a positive impact on recalcification in the irradiated site 
[44]. This study also founded that a haemoglobin level of less than 80 g/l, clinical stage II 
according to Durie-Salmon and a decrease in pain in the irradiated site are significant param-
eters for the recalcification [44].
The clinical study performed by Mose et al. showed that higher recalcification rates depend 
on the usage of bisphosphonates [12], but other study did not demonstrate such a relation [5]. 
In the clinical study reported by Rudzianskiene et al., the use of bisphosphonates was also an 
insignificant parameter but this may be due to the small sample of patients (only 18%) taking 
bisphosphonates [44].
Results of recalcification response from clinical trials of palliative radiotherapy in the treat-
ment of MM patients are shown in Table 3.
4.3. The treatment of spinal cord compression
Epidural spinal cord compression that can cause pain and neurological impairment occurs 
in 5–20% of all patients with multiple myeloma at various disease stages and leads to dis-
ability [46, 47]. Pain is the first and more common presenting symptom followed by motor 
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deficiency, sensory symptoms and bowel and bladder dysfunction [48]. Immediate diagnosis 
and treatment are very important in the preservation of neurological function in patients with 
spinal cord compression. Pain control, relief of spinal cord compression and improvement of 
neurologic function are the main goals of treatment. High-dose steroids must soon be initi-
ated upon spinal cord compression diagnosed to obtain an antineoplastic and an antioedema 
effect [49]. In patients with neurologic symptoms directly due to cord compression, radiation 
therapy is given along with dexamethasone, and up to half of patients may have improve-
ment of motor function [50]. In the largest retrospective studies, radiotherapy alone improves 
motor function in 75% of patients with spinal cord compression due to MM. A 1-year local 
control was 100% and a 1-year survival was 94% [51].
Radiation treatment can be used as fractionated external beam radiotherapy (EBRT) or 
stereotactic body RT (SBRT). Both methods are effective for palliative treatment and local 
tumour control. SBRT is a non-invasive treatment option for spinal disease in the absence of a 
high-grade spinal cord compression. SBRT allows the treatment of small- or moderate-sized 
tumours, even in close proximity to the spinal cord, in either a single or a limited number of 
dose fractions [48]. SBRT with a single 24 Gy fraction gives excellent tumour control [48].
Since myeloma is a very radiosensitive tumour, EBRT is an appropriate approach for patients 
who are not considered surgical treatment and it is also indicated after decompression inter-
vention. There was no randomised trial that compared radiotherapy alone to radiotherapy 
plus upfront neurosurgery. Thus, radiotherapy alone is considered the standard treatment of 
Clinical study Number 
of 
patients
Number of 
irradiated 
sites
Total 
dose 
(Gy)
Overall 
response 
(%)
Comments
Stolting et al. [5] 138 272 2–60 44.7 There was no significance difference 
between recalcification response 
and higher radiation dose, usage 
of bisphosphonates, concurrent 
chemotherapy increase response of 
recalcification.
Balducci et al. [7] 52 52 16–50 50 The influence of total radiation 
dose, concurrent chemotherapy and 
bisphosphonates was not evaluated.
Mose et al. [12] 42 71 18–45 46.4 There was no significance difference 
between recalcification response and total 
radiation dose, concurrent chemotherapy 
and bisphosphonates increase response of 
recalcification.
Rudzianskiene et al. 
[44]
101 101 8 Gy vs. 
30 Gy
35.9 vs. 
32.1
There was no significant difference 
between recalcification response 
and higher radiation dose, usage of 
bisphosphonates and there was no 
influence of concurrent chemotherapy.
Table 3. A summary of published data on palliative radiotherapy recalcification response in the treatment of patients 
with MM.
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SCC from myeloma [52]. Several fractionation regimens: single-fraction, short-course multi-
fraction and longer-course multi-fraction regimens are used for the treatment of spinal cord 
compression. Radiotherapy either 30 Gy in 10 fractions or lower radiation doses must be 
provided as an optimal approach causing the long-lasting local control [50]. Several clinical 
studies have examined the impact of multi-fraction regimens versus single-fraction regimens 
on pain relief and functional outcomes, local tumour control and overall survival [12, 52–55]. 
Rades et al. compared short-course 8 Gy in one fraction or 20 Gy in five fraction regimens 
with long-course 30–40 Gy in 10–20 fraction regimens [53]. There were no significant differ-
ences in functional or overall survival between the groups. However, a better local control (77 
vs. 61%) and a 12-month progression-free survival (72 vs. 55%) were significantly better in 
long-course radiotherapy regimen group [53]. A phase III randomised multicentre Italian trial 
demonstrated a similar effect in functional outcomes and overall survival between two frac-
tions of 8 Gy (16 Gy total dose) or a single dose of 8 Gy radiotherapy in patients with spinal 
cord compression and a short life expectancy [54].
Multiple myeloma patients with spinal cord compression have a comparably good survival, 
living for years after treatment in the era of novel drugs [55]. Only very few clinical stud-
ies can be found in the study, investigating radiotherapy of spinal cord compression in MM 
patients [12, 52, 55], and the appropriate radiotherapy regimen for the treatment of spinal 
cord compression in MM patients has not been defined yet. Rades et al. reported that the 
improvement of motor function was more frequent after long-course radiotherapy than after 
short-course at 6 months (67 vs. 43%) and at 12 months (76 vs. 40%) [55]. However, Mose et al. 
demonstrated that 65% of patients with spinal cord compression after radiotherapy experi-
enced neurological improvement, and Karnofsky index, gender, age, site of myelocompres-
sion and the total radiation dose did not influence this effect [12].
One retrospective study was performed to find a predictive tool that allows the estimation of 
overall survival (OS) of elderly myeloma patients (aged ≥65 years) presenting with myeloma-
induced spinal cord compression [52]. Rades et al. found that myeloma type (HR 3.31; 95% CI 
1.75–6.49; p < 0.001), ECOG-PS (HR 5.33; 95% CI 2.67–11.11; p < 0.001), ambulatory status (HR 
2.71; 95% CI 1.65–4.57; p < 0.001) and age (HR 1.95; 95% CI 1.03–3.78; p = 0.040) were signifi-
cantly associated with survival, but fractionation regimen was not a predictive tool for OS [52].
The choice of radiotherapy regimen in the treatment of spinal cord compression should be 
based on the expectancy of patient’s life. Longer-course programs, which result in a better 
local control than single-fraction and short-course programs, are the preferred treatment for 
patients with a more favourable survival prognosis. By contrast, patients with a poor progno-
sis are better candidates for multi-fraction short-course or single-fraction radiotherapy [52].
5. Surgery and radiation treatment
Surgical management of MM-related bone lesions sometimes is carried out due to disease 
sensitivity of radiation treatment and chemotherapy. The most common indications for sur-
gical procedures are unstable fractures and spinal cord compression when bone fragments 
The Role of Radiology and Radiotherapy for Multiple Myeloma
http://dx.doi.org/10.5772/intechopen.75397
171
protrude from a vertebral fracture [49]. Vertebroplasty and kyphoplasty are carried out by 
fibroscopic percutaneous injection of polymethylmethacrylate into the fractured vertebrae 
in order to relieve pain. These procedures should be considered for symptomatic vertebral 
compression fractures, and this is a procedure of choice to improve the quality of life [3]. 
Vertebroplasty combined with post-operative radiotherapy is an effective approach in the 
pain palliation, maintaining the stability of vertebral column and improving the quality of life 
of patients. Some randomised clinical studies demonstrated that surgery and post-operative 
radiotherapy are more effective in the treatment of vertebral fractures than radiotherapy 
alone [56, 57]. Treating these patients with radiotherapy before surgery procedure allows for 
tumour shrinkage and can enable these patients to become candidates for vertebroplasty [58]. 
The study performed by Hirsch et al. reported that the timing of radiotherapy, before or after 
vertebroplasty, did not significantly impact outcomes of these procedures [58].
6. Side effects
Radiotherapy is generally well tolerated. The external beam localised fields’ radiotherapy 
offers advantage of few acute and late toxicities. The potential side effects of radiotherapy are 
related to the fraction dose, total radiation dose, volume of the target, toxicities from other 
treatment approaches and the radiosensitivity of healthy surrounding tissues. The radiother-
apy planning process uses established tolerance doses to avoid irreversible damage of critical 
organs, such as the lung, kidney, liver and spinal cord. Organ tolerances are based on the con-
ventional radiotherapy (1.8–2 Gy per fraction daily, five times a week). When unconventional 
Acute side effects
Clinical manifestation
Systemic side effects Fatigue, anorexia, nausea/vomiting
Skin Erythema, itching, dry desquamation, blister formation, hair loss in the treatment area
Mouth, oesophagus Sore throat, dry mouth, trouble swallowing, taste loss
Small/large intestine Loose stools/diarrhoea, cramps, bleeding, incontinence, rectal irritation
Haematologic Neutropaenia, anaemia, thrombocytopaenia
Bladder Bladder spasms, cystitis, urinary frequency, incontinence, haematuria
Late side effects
Skin Telangiectasia, atrophy, ulceration, pigmentation changes
Mouth, oesophagus Xerostomia, sialitis, difficulty in swallowing, ulceration, trismus, osteoradionecrosis, 
fistula
Small/large intestine Diarrhoea, cramping/colic, bowel movement, obstruction, bleeding, fistula, necrosis
Bladder Haematuria, epithelial atrophy, reduction in bladder capacity
Table 4. A summary of most common side effects of radiation treatment.
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fractionation regimens are introduced, the total radiation dose must be adjusted to avoid high 
risk of side effects, as lower total doses limit acute toxicity. In general, palliative radiotherapy 
doses are delivered with a larger dose per fraction. These hypofractionated regimens may 
provide the benefit of earlier response but with a greater risk of late side effects [59]. Late side 
effects occur from months to years after radiation treatment, and patients with a short life 
expectancy may not live long enough to experience such risks.
Side effects of radiation are generally mild, limited to the radiotherapy site and can be pre-
dicted. Most acute side effects arising within 90 days are self-limited, lasting days to weeks 
and resolve within few weeks with supportive care. Acute toxicities as fatigue, nausea/vom-
iting, mucositis, oesophagitis and bowel irritation are often easily managed and reversible. 
The more critical side effects are late side effects, emergent from cellular and vascular atro-
phy, and lead to the reduction of normal tissue function and organ dysfunction, which may 
develop months to years later, but they are very rare.
In 1982, the Radiation Therapy Oncology Group (RTOG) developed the Radiation Morbidity 
Scoring Criteria to classify radiotherapy effects. RTOG score has been widely employed and 
is accepted and acknowledged by medical communities [60].
Skin reactions are usually nominal during radiation treatment for bone metastases and are 
treated similar to burns. Patients treated with large volumes including pelvis, epigastrium 
or thoracolumbar spine region may experience nausea and/or vomiting. Prophylactic anti-
emetics can be administered 30–60 min prior to radiotherapy and continued on as needed. 
Hematologic side effects are mild and transient, but bone marrow suppression may occur if 
the patients are receiving treatment to large targets, when the total radiation dose is moderate 
or high, and a significant proportion of marrow is included, especially in heavily pretreated 
patients. Mucositis and oesophagitis causing difficult and painful swallowing occur after 
treatment to the head and neck or thorax. It should be treated with dietary modifications, 
oral rinses, antifungals, analgesics and cytoprotective agents. Radiation enteritis manifested 
by cramping; frequent, loose stools and occasionally bleeding may occur if large amounts of 
small intestine are included. Treating the pelvis may also result in short-lived diarrhoea [61]. 
A summary of clinical manifestations of the most common side effects of radiation treatment 
is shown in Table 4.
No significant differences were observed between SF and MF radiotherapy for bone metasta-
ses of solid tumours in the systematic review performed by Chow et al. [30]. Only two studies 
reported more acute toxicities (characterised as grades 2–4) in the group of MF regimens than 
in SF [30].
Based on the analysis of medical literature, the side effects of radiotherapy in multiple 
myeloma patients were generally mild. Balducci et al. [7] identified 44% of patients (n = 23) 
with side effects (grades 1–2): haematological toxicity in 48%, gastroenteric toxicity in 26%, 
pharyngeal toxicity in 9% and cutaneous toxicity in 17% patients. Mose et al. [12] reported 
about 54% side effects mostly of grades 1–2; grade 3 in 4% (haematological side effects, muco-
sitis, creatinine level). These data correspond with Matuschek et al. [62] as this study reported 
37% side effects with 50% grade 1 and 47.2% grade 2 and one patient grade 3 dysphagia.
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7. Conclusions
Radiotherapy continues to be an effective palliative treatment approach in the management of 
bone disease in MM patients inducing an analgesic effect in osteolytic lesions, promoting recal-
cification in the sites of impending pathological fractures and controlling the symptoms in spi-
nal cord compression without significant toxicity. No difference in the efficacy for pain relief 
and recalcification has been observed using different radiotherapy regimens. However, the 
choice of radiotherapy regimen in the treatment of spinal cord compression should be based 
on the expectancy of patient’s survival. Multi-fraction regimens, which result in a better local 
control, are the preferred treatment for patients with a more favourable survival prognosis.
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